Objective-Cell-surface localization and intracellular trafficking are essential for the function of ATP-binding cassette transporter A-1 (ABCA1). However, regulation of these activities is still largely unknown. Brefeldin A, an uncompetitive inhibitor of brefeldin A-inhibited guanine nucleotide-exchange proteins (BIGs), disturbs the intracellular distribution of ABCA1, and thus inhibits cholesterol efflux. This study aimed to define the possible roles of BIGs in regulating ABCA1 trafficking and cholesterol efflux, and further to explore the potential mechanism. Methods and Results-By vesicle immunoprecipitation, we found that BIG1 was associated with ABCA1 in vesicles preparation from rat liver. BIG1 depletion reduced surface ABCA1 on HepG2 cells, and inhibited by 60% cholesterol release. In contrast, BIG1 overexpression increased surface ABCA1 and cholesterol secretion. With partial restoration of BIG1 through overexpression in BIG1-depleted cells, surface ABCA1 was also restored. Biotinylation and glutathione cleavage revealed that BIG1 small interfering RNA dramatically decreased the internalization and recycling of ABCA1. This novel function of BIG1 was dependent on the guanine nucleotide-exchange activity and achieved through activation of ADP-ribosylation factor 1. Conclusion-BIG1, through its ability to activate ADP-ribosylation factor 1, regulates cell-surface levels and function of ABCA1, indicating a transcription-independent mechanism for controlling ABCA1 action. (Arterioscler Thromb Vasc Biol. 2013;33:e31-e38.)
T he ATP-binding cassette transporter A-1 (ABCA1) belongs to the ATP-binding cassette superfamily of integral membrane proteins that are responsible for the ATPpowered translocation of cholesterol, phospholipids, and other substrates across membranes. 1 The discovery that mutations in the ABCA1 gene cause Tangier disease and familial hypoalphalipoproteinemia clearly demonstrated ABCA1 as the key protein responsible for nascent high-density lipoprotein (HDL) particle, and a critical molecule regulating an initial step of reverse cholesterol transport. 2, 3 Thus, ABCA1 has been considered as a potential target in the treatment of atherosclerotic vascular disease. 4 ABCA1 mostly localizes to the plasma membrane (PM) and endocytic vesicles, and rapidly shuttles between the cell surface and intracellular compartments. 5, 6 The importance of its PM localization for proper ABCA1 function has been confirmed by a number of independent studies. [7] [8] [9] Trafficking of ABCA1 between specific intracellular and PM sites is exquisitely controlled, and is essential for regulation of intracellular cholesterol. Decreasing ABCA1 internalization by deletion of its PEST sequence leads to decreased cholesterol efflux from late endosomal cholesterol pools. 10 Overexpression of the small GTPase Rab8, which is involved in trafficking from the trans-Golgi network (TGN) to the PM and from the endosomes to the PM, facilitates ABCA1 surface expression and stimulates the delivery of cholesterol from late endosomal compartments to apolipoprotein A-I (apoA-I). 11, 12 However, the processes regulating specific subcellular localization of ABCA1 are still largely unknown.
Brefeldin A (BFA), an uncompetitive inhibitor of ADPribosylation factor (ARF)-guanine nucleotide-exchange factor (GEF) activity, has been reported to disturb the dynamics and intracellular distribution of ABCA1, and thus inhibit cholesterol efflux. 6, 13, 14 Through binding the ARF-GDP-ARF-GEF complex, BFA locks it in a conformation that prevents nucleotide dissociation, resulting in specific blockade of ARF activation by a subset of its GEFs, and thus interferes reversibly with vesicular transport between the cell surface and intracellular compartments. 15, 16 There are 3 BFAsensitive GEFs: brefeldin A-inhibited guanine nucleotideexchange protein (BIG) 1, BIG2, and Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1). BIG1 and BIG2 are 74% identical in amino acid sequence and 90% identical in Sec7 domains that are responsible for ARF activation. Both BIG1 and BIG2 are associated mainly with the regulation of trafficking through TGN and endosomes, 17, 18 whereas GBF1 functions primarily in transport between ERGolgi intermediate and cis-Golgi compartments. 19 Therefore, we hypothesized that BIGs might play a role in regulating ABCA1 transport and function.
Here, we present evidence that BIG1 is associated with ABCA1 in vesicles from rat liver. BIG1, but not BIG2, was required for trafficking and surface localization of ABCA1. Moreover, we demonstrated that BIG1 activity was crucial for ABCA1 function in cholesterol efflux. This study evaluated whether BIG1-mediated vesicle trafficking represents a transcription-independent mechanism for regulation of ABCA1 function.
Materials and Methods
A detailed Materials and Methods section is presented in the onlineonly Data Supplement.
Vesicle Immunoprecipitation
Membranes from rat liver were subjected to differential centrifugation. Fractions containing vesicles enriched in clathrin and adaptor protein-1 were used for vesicle immunoprecipitation (IP) by magnetic Dynabeads (Dynal).
Labeling and Tracing of ABCA1
Cell-surface proteins were biotinylated with EZ-Link Sulfo-NHS-SSBiotin (Pierce) and isolated by incubating with streptavidin-agarose beads (Pierce). Biotinylated proteins remaining on the cell surface after internalization or recycling were cleaved by reduced glutathione (pH 8.0).
Results

Association of ABCA1 With BIG1 In Vivo and In Vitro
Because BFA, an inhibitor of BIG1 and BIG2 GEF activity, was reported to inhibit cholesterol efflux by disturbing intracellular trafficking of ABCA1, 6, 13, 14, 20 we hypothesized that BIGs might play a role in regulating ABCA1 transport and function. BIGs have been found in trans-Golgi compartments and colocalized with clathrin and adaptor protein-1. 21, 22 To test the hypothesis, membrane fractions containing vesicles enriched in clathrin and adaptor protein-1 from rat liver were immunoprecipitated with anti-BIG1 or BIG2 antibodies. ABCA1 was detected in the vesicle preparation by anti-BIG1 pull-down ( Figure 1A ), indicating colocalization of the 2 proteins in the same vesicle complex.
Sustained uptake of cholesterol by human macrophages upregulates ABCA1 expression. 23, 24 ABCA1 levels in liver cells, but not macrophages, modulate susceptibility to atherosclerosis. 25 To explore the possible mutual regulation of ABCA1 and BIG1 in hyperlipidemia, apoE −/− mice with their genetic abnormalities in lipid metabolism were used. As reported, 26 atorvastatin dose-dependently reduced serum lipid content (serum total cholesterol, triglycerides, and lowdensity lipoprotein [LDL] cholesterol) in apoE −/− mice fed with high-fat diet ( Figure IA in the online-only Data Supplement). Hepatic levels of ABCA1 and BIG1 were significantly higher in apoE −/− mice than wild-type (WT) mice, and were decreased by atorvastatin in a dose-dependent fashion ( Figure IB in the online-only Data Supplement). The concurrent changes in amounts of BIG1 and ABCA1 in liver together with the co-IP suggests a close relationship between the two proteins in vivo.
Oxidized low-density lipoprotein (oxLDL) has been implicated in the pathogenesis of atherosclerosis, and reported to upregulate ABCA1 gene expression through activation of the nuclear liver X receptors. 27 In HepG2 cells, ABCA1 and BIG1 protein expression increased significantly after addition of oxLDL. Upregulation as a result of oxLDL exposure was inhibited in a dose-dependent manner by atorvastatin ( Figure 1B ), but atorvastatin had no effect on the expression of BIG1 or ABCA1, without oxLDL treatment ( Figure 1C ). In BIG1-depleted cells, oxLDL did not alter BIG1 expression, and the increase in ABCA1 by oxLDL stimulation was partly inhibited ( Figure 1D ). ApoA-I has been demonstrated also to increase ABCA1 levels by binding to and preventing degradation of the ABCA1 transporter. 28, 29 Treatment of cells with apoA-I increased ABCA1 without affecting BIG1 level ( Figure 1E ). These observations suggest that the expression of ABCA1 and BIG1 were modulated by cell lipid content, which differs from the apoA-I-ABCA1 interaction.
Function of ABCA1 in HepG2 Cells Requires BIG1, but Not BIG2
To explore roles of BIG1 and BIG2 in apoA-I-ABCA1-dependent cholesterol efflux, we used small interfering RNA to deplete BIG1 or BIG2 in HepG2 cells ( Figure 2A ). As shown in Figure 2B , only BIG1 small interfering RNA reduced cholesterol efflux to apoA-I (≈60% decrease) by HepG2 cells. Similarly, decreased release of cellular cholesterol into HepG2 cell culture medium was observed only in BIG1-depleted cells by Amplex Red cholesterol Assay ( Figure 2C ). Cholesterol accumulation was evaluated by staining fixed cells with filipin, a specific marker for unesterified cholesterol. We observed a significant accumulation of filipin staining in BIG1-depleted cells compared with Mock, nontargeting, or BIG2-depleted cells ( Figure 2D ), corresponding to the decreased efflux ( Figure 2B ). The amount of apoA-I present in cells and in medium was also detected by Western blot. In BIG1-depleted cells, both cell-associated and medium apoA-I were decreased ( Figure 2E ). The mRNA level of apoA-I was also measured by real-time PCR. Our result revealed that apoA-I mRNA slightly increased in BIG1-depleted cells, but failed to reach statistical significance ( Figure 2E ; P>0.05). Together, these findings are consistent with a role for BIG1 in ABCA1-mediated lipidation of apoA-I. e33
BIG1 Is Required for Targeting of ABCA1 to the PM
Because localization of ABCA1 at the PM is vital for its lipid transport function, we hypothesized that BIG1 may play a role in targeting of ABCA1 to the PM. As shown in Figure 3A , surface ABCA1 of HepG2 or differentiated THP1 cells decreased significantly after BIG1-depletion, but total ABCA1 content was unchanged. To further verify our hypothesis, we overexpressed BIG1 in nontreated or BIG1-depleted cells. Expression of green fluorescent protein-BIG1 (WT) increased cell-surface ABCA1 without affecting the total content of ABCA1. In contrast, overexpression of hemagglutinin-BIG1 (E793K), a dominant-negative mutant, which does not activate ARFs, had no effect on total amount or the surface level of ABCA1 ( Figure 3B ). In addition, overexpression of BIG1-WT partially reversed the reduction in surface ABCA1, in cells treated by BIG1 small interfering RNA ( Figure 3C ). Consistent with increased content of cell-surface ABCA1 after BIG1-WT expression, an increase in the amount of cholesterol in the culture medium was observed after BIG1-WT, but not hemagglutinin-BIG1 (E793K), overexpression ( Figure 3D ). A reverse situation was seen in BFA-treated cells ( Figure 3E ). The medium cholesterol content correlated with the level of cell-surface ABCA1. Differences between effects of BIG1-E793K overexpression and BIG1 depletion on surface ABCA1 expression and secreted cholesterol could be caused by low efficiency of plasmid transfection.
BIG1 Depletion Inhibited ABCA1 Internalization and Recycling
ABCA1/apoA-I retroendocytosis was reported to contribute significantly to HDL formation, when cells had accumulated excess cholesterol. 30 To further elucidate the intracellular pathways of ABCA1 trafficking after BIG1-depletion, the internalization and recycling of surface ABCA1 were traced. Cell-surface proteins were biotinylated and allowed to internalize for indicated time. Proteins remaining on the cell surface were cleaved by reduced glutathione. Internalized biotinylated proteins were isolated by streptavidin-agarose beads. As shown in Figure 4A , the internalized ABCA1 in BIG1-depleted cells was much less than in nontargeting control cells, indicating a dramatically decreased capability of internalization in BIG1-depleted cells. Furthermore, the amount of ABCA1 recycling back to the cell surface was also reduced by BIG1-depletion. Although both internalization and recycling were inhibited by BIG1 depletion, some ABCA1 was still transported between the PM and intracellular compartments ( Figure 4B ). As ABCA1 was reported to cycle intracellularly via a Rab4-or Rab8-mediated pathway, 12, 31 it is conceivable that BIG1 participates in only one part of the whole recycling process.
In HeLa cells without endogenous ABCA1, stably expressed ABCA1-green fluorescent protein resides on the surface and also in intracellular endosomes ( Figure III in the online-only Data Supplement). Depletion of endogenous BIG1 resulted in a loss of filipin-labeling in endosome-like clusters and exhibited much greater accumulation of intracellular cholesterol ( Figure  4C ), suggesting that mobilization of cellular ABCA1-green fluorescent protein through BIG1 contributed significantly to cholesterol release. Sucrose gradient fractionation also revealed that BIG1 depletion significantly affected the distribution of ABCA1 and late endosome marker Rab7, but had no effect on early endosome marker EEA1, recycling endosome marker transferrin receptor, or lysosome marker lamp2. ABCA1 in fractions 2, 3, and 6 in which enriched EEA1 and Rab7 were absent in BIG1-depleted cells indicated that the recycling of ABCA1 was partly eliminated ( Figure IV in the online-only Data Supplement).
Regulation of BIG1 in Surface Localization and Function of ABCA1 Was Achieved Through Activation of ARF1
BIG1 functions as an activator of ARFs, which are major regulators of membrane remodeling and protein trafficking in eukaryotic cells. Our results from BIG1-E793K overexpression and BFA inhibition indicated that effects of BIG1 on the surface localization and function of ABCA1 were dependent on its GEF activity. To determine whether the activation of ARFs is truly indispensable for ABCA1 function, we compared the distribution of ARF (1, 3, 4, 5, and 6) between cytosol and membrane of HepG2 cells treated with nontargeting, or specific BIG1 or BIG2 small interfering RNA, or vehicle alone (Mock). Only ARF1, which localizes primarily to the Golgi apparatus, known to regulate both anterograde and retrograde vesicular traffic, 32 was found to be decreased in membrane fractions after BIG1 depletion ( Figure 5A ). To assess the potential involvement of ARF1 in the BIG1-ABCA1 interaction, constructs of WT and 2 mutants of ARF1 with myc tags were prepared for transient overexpression. Cells overexpressing ARF1-Q71L, which is assumed to be constitutively active with GTP-bound, or WT-ARF1, showed increased surface ABCA1. In addition, ARF-Q71L stimulated a much greater surface distribution of ABCA1 than ARF1-WT. However, in cells expressing inactive ARF1-T31N, surface ABCA1 was not affected. No change was seen in total ABCA1 after plasmid transfection. Cholesterol secreted in the culture medium was also measured using the Amplex Red Cholesterol Assay Kit. An increased cholesterol content was found in cells overexpressing Arf1-WT and Arf1-Q71L ( Figure 5C ). There were no significant differences in the levels of total cell cholesterol.
Discussion
ABCA1 is widely expressed in nearly all tissues of the body, and is particularly abundant in the liver. Findings from studies of hepatic overexpression of ABCA1 suggested that the liver itself is a major source of cholesterol for both ]-labeled cholesterol, followed by efflux to apoA-I (10 μg/mL). Mock was used as a control (set at 100%). n=3; ***P<0.001. C, After nontargeting, BIG1, or BIG2 small interfering RNA treatment, cholesterol content in condition medium was measured by the Amplex Red Cholesterol Assay Kit (n=6, ***P<0.001). D, Cholesterol accumulation in HepG2 cells after small interfering RNA was displayed by filipin-labeling. The images were taken using a confocal microscope (Zeiss 710). E, HepG2 cells were incubated with vehicle (Mock) or with nontargeting or BIG1 small interfering RNA for 72 hours. The levels of apoA I in total cell lysates (T) or culture medium (S) after trichloroacetic acid (TCA) precipitation were detected by Western blotting. The levels of BIG1 and apoA-I mRNA were detected by real-time PCR. ***P<0.001 vs non-targeting.
plasma HDL acceptors and nascent HDL particles, which mediate cholesterol efflux from peripheral cells. 33, 34 More important, results from liver-specific ABCA1-knockout mice demonstrated that hepatic ABCA1 is the single most important source of nascent apoA-I, and maintains the majority of the plasma HDL pool. 35 Studies using ABCA1-knockout bone marrow transplanted into WT mice demonstrated that ABCA1-mediated cholesterol efflux from macrophages did not significantly contribute to plasma HDL cholesterol level. 36 These combined results indicate that appropriate regulation of hepatic ABCA1 is critical for a selective increase in HDL cholesterol levels. It is thus important to understand how the expression and function of ABCA1 is regulated in hepatocytes. In our study, we used the human hepatoma cell line HepG2 as a model system, combined with rat liver and apoE -/-mice, to identify BIG1 as the novel regulator of ABCA1, and to demonstrate the underlying mechanism. BFA, often used as an inhibitor of vesicle trafficking between the TGN and PM, inhibits the activity of ARF-GEFs and arrests ARFs in the GDP-bound form. 37 It was reported that BFA disturbed the dynamics and intracellular distribution of ABCA1, 6 and inhibited apoA-I-mediated lipid efflux from macrophages and fibroblasts. 20 Therefore, we hypothesized that BIGs, BFA-sensitive ARF-GEFs, might play a role in regulating ABCA1 transport and function. To identify BIGs involvement in the regulation of hepatic ABCA1 function, vesicles isolated from rat liver were immunoprecipitated with anti-BIG1 or BIG2 antibodies. Interestingly, ABCA1 was present in vesicles precipitated with the anti-BIG1, but not anti-BIG2, antibodies, indicating a potential interaction between the 2 proteins. It has been clearly established that regulation of ABCA1 expression is primarily via cellular cholesterol level, through the nuclear receptor liver X receptor. 38 To explore the possible regulation of BIG1 in hepatic ABCA1 function, the relationship between varying BIG1 and ABCA1 expression in liver was observed. In apoE −/− mice fed with high-fat diet, increased hepatic ABCA1 and BIG1 were found along with high serum lipid content (serum total cholesterol, triglycerides, and LDL cholesterol). When serum lipids were decreased by atorvastatin treatment, both ABCA1 and BIG1 were downregulated. Consistent with in vivo findings, high concentrations of oxLDL increased both ABCA1 and BIG1 proteins in HepG2 cells. Increases in ABCA1 and BIG1 were counteracted by atorvastatin treatment in a dose-dependent manner. BIG1 depletion, however, had no effect on total amount of ABCA1, but reduced the elevation of ABCA1 induced by oxLDL. Concurrently increased or decreased levels of BIG1 and ABCA1, together with the co-IP of ABCA1-BIG1 in hepatic vesicles, identified a novel interaction between the 2 proteins. Regulation of ABCA1 at the PM and endocytic compartments is important for lipid processing because the functionality of ABCA1 at these sites is considered essential for the initiation of cholesterol removal from cells. 5, 6 We showed that BIG1 overexpression increased levels of surface ABCA1, and facilitated HepG2 cells to discard excess cholesterol when exposed to oxLDL. In BIG1-depleted cells with partial restoration of BIG1 through overexpression, ABCA1 localization at the PM was also restored, consistent with a role for BIG1 in the process. Recycling of ABCA1 from endocytic compartments to the PM was markedly reduced in BIG1-depleted cells. Because of these findings and the discovery of the interaction between BIG1 and ABCA1, it seems likely that BIG1 plays a significant role in the pathophysiology of atherosclerosis.
BIG1 is often found in trans-Golgi compartments and colocalizes with clathrin and adaptor protein-1. 21, 22 Silencing of BIG1 expression can halt protein trafficking at sites where it is required to activate ARFs, and thereby initiate vesicle generation for the next stage of transport to the cell surface. Our previous studies revealed that BIG1 is required for integrity of the Golgi structure. 39 Kinesin family member 21A, a plusend-directed motor protein that moves cargo on microtubules away from TGN, was identified as a novel binding partner of BIG1. The newly recognized interaction integrates functions of BIG1 in local vesicle formation with longer range transport processes toward the cell surface. 40 Thus, it appears that BIG1 regulates ABCA1 cell-surface expression via governing its internalization and trafficking. It has been clearly established that the PM is an important site at which ABCA1 plays an antiatherogenic role. [7] [8] [9] Internalization and trafficking of ABCA1 is functionally important in mediating ABCA1 cellsurface expression, as well as cholesterol efflux from intracellular cholesterol pools. 41 Like the other cell-surface proteins, once ABCA1 arrives at the TGN, it is sorted for delivery over long distances to the PM by large membrane carriers, in which BIG1 has been found to be involved. 40 Consistent with the role of BIG1 in that process, our results from BIG1 depletion or overexpression revealed that BIG1 is required to maintain surface ABCA1 levels and cholesterol efflux to apoA-I. Further, results from tracing the internalization and recycling of surface ABCA1 after BIG1-depletion revealed a dramatic inhibition of the capability of internalization and recycling. In HeLa cells stably expressing ABCA1-green fluorescent protein, depletion of endogenous BIG1 resulted in loss of endosome-like filipin-labeling clusters and exhibited much more intracellular cholesterol accumulation, consistent with the findings from internalization and recycling. However, some ABCA1 was still transported between the PM and intracellular compartments after BIG1 depletion, indicating that other pathways also participate in the recycling of ABCA1, such as the Rab4-or Rab8-mediated pathway. 12, 31 In the present study, the effects of BIG1 on cell-surface ABCA1 expression and cholesterol secretion is dependent on its GEF activity, as dominant-negative BIG1 overexpression did not increase surface ABCA1 levels and promote cholesterol secretion, as did WT BIG1. Previous studies reported that BIG1 preferentially functions as a GEF of class I ARFs (ARF1 and ARF3), by catalyzing replacement of ARF-bound GDP with GTP. 42 We found that BIG1 depletion decreased membrane binding by ARF1 in HepG2 cells, consistent with decreased ARF1 activity. Overexpression of WT ARF1 resulted in increased cell-surface ABCA1, which was even more enhanced by the constitutively active ARF1 (Q71L) mutant, suggesting that ARF1 activation is important for ABCA1 surface localization regulated by BIG1. Actually, ARF-like 7 has been found to be involved in transport between the perinuclear compartment and the PM, apparently linked to the ABCA1-mediated cholesterol secretion pathway. 43 Nevertheless, the dominant-negative ARF1 (T31N) exhibited no obvious suppression of surface ABCA1 or cholesterol secretion, perhaps because of low levels of the mutant proteins. Both BIG1 and ARF1 have been reported to function in the Golgi complex and clathrin-coated vesicles. 21, 22, 44 The ABCA1/apoA-I complex is also endocytosed via the clathrin pathway. 30 It appears that the newly synthesized ABCA1 is transported to the surface in the same manner. Clearly, further studies are required to evaluate these possibilities.
In summary, the present work identifies BIG1 as an important intracellular regulator that mediates cell-surface ABCA1 expression, and facilitates cholesterol efflux to apoA-I by governing its intracellular trafficking. This novel function of BIG1 requires GEF activity to accelerate activation of ARF1. Interestingly, a xLxxKN motif serves as a Golgi exit signal and directs ABCA transporters to a post-Golgi vesicular sorting station, where additional signals may be required for selective delivery of individual transporters to final subcellular destinations. 45 Thus, BIG1 regulation may be related to xLxxKN motif, which requires further research. Our study represents a transcription-independent mechanism for regulating ABCA1 function. 
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